Effectiveness of tildrakizumab 200 mg: an Italian multicenter study
Introduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2420825 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850250042501234688 |
|---|---|
| author | Annunziata Dattola Nicoletta Bernardini Francesca Svara Anna Balato Giacomo Caldarola Domenico D’Amico Clara De Simone Eugenia Veronica Di Brizzi Maria Esposito Claudia Giofrè Domenico Giordano Claudio Guarneri Francesco Loconsole Viviana Lora Gaia Moretta Diego Orsini Severino Persechino Concetta Potenza Simone Ragonesi Giovanni Pellacani Ketty Peris Maria Concetta Fargnoli Antonio Giovanni Richetta |
| author_facet | Annunziata Dattola Nicoletta Bernardini Francesca Svara Anna Balato Giacomo Caldarola Domenico D’Amico Clara De Simone Eugenia Veronica Di Brizzi Maria Esposito Claudia Giofrè Domenico Giordano Claudio Guarneri Francesco Loconsole Viviana Lora Gaia Moretta Diego Orsini Severino Persechino Concetta Potenza Simone Ragonesi Giovanni Pellacani Ketty Peris Maria Concetta Fargnoli Antonio Giovanni Richetta |
| author_sort | Annunziata Dattola |
| collection | DOAJ |
| description | Introduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden.Methods: This multicenter, prospective study evaluated the effectiveness and safety of tildrakizumab 200 mg in patients with moderate-to-severe psoriasis, focusing on those with specific challenges: body weight over 90 kg, baseline PASI ≥20, and difficult-to-treat areas. The study also compared bio-naive versus bio-experienced and male versus female patients. Adults received tildrakizumab 200 mg subcutaneously at weeks 0 and 4, then every 12 weeks.Results: Clinical improvements were assessed using PASI, DLQI, genital PASI, and NAPSI scores. After 24 weeks, the mean PASI score dropped from 14.6 to 0.4, with PASI 90 and PASI 100 scores exceeding 80% (100.0% and 80.3%, respectively). DLQI scores improved from 14.2 to 1.8, and significant improvements were seen in genital PASI and NAPSI scores. No significant adverse events occurred.Conclusions: Tildrakizumab 200 has been shown to be an effective therapeutic option, particularly for patients with high body weight, significant disease burden, and involvement of sensitive areas with no new safety signals. |
| format | Article |
| id | doaj-art-0025053498fe49b2841bd41e99bc2742 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-0025053498fe49b2841bd41e99bc27422025-08-20T01:58:20ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2420825Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola0Nicoletta Bernardini1Francesca Svara2Anna Balato3Giacomo Caldarola4Domenico D’Amico5Clara De Simone6Eugenia Veronica Di Brizzi7Maria Esposito8Claudia Giofrè9Domenico Giordano10Claudio Guarneri11Francesco Loconsole12Viviana Lora13Gaia Moretta14Diego Orsini15Severino Persechino16Concetta Potenza17Simone Ragonesi18Giovanni Pellacani19Ketty Peris20Maria Concetta Fargnoli21Antonio Giovanni Richetta22Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ItalyInstitute of Dermatology, Università Cattolica del Sacro Cuore, Rome, ItalyDermatology unit in Hospital Facility “A. Pugliese” and UOC "R.Dulbecco", Catanzaro, ItalyInstitute of Dermatology, Università Cattolica del Sacro Cuore, Rome, ItalyDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyDermatology UOC “Papardo” Hospital, Messina, ItalySant’Andrea Hospital University of Rome, Rome, ItalyDepartment of Biomedical, Dental Sciences and Morphofunctional Imaging, Section of Dermatology, University of Messina, Messina, ItalyDivision of Dermatology, University Hospital Consorziale, Bari, ItalyDivision of Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyDepartment of Dermatology, Istituto Dermopatico dell’Immacolata IRCCSRome, ItalyDivision of Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalySant’Andrea Hospital University of Rome, Rome, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyInstitute of Dermatology, Università Cattolica del Sacro Cuore, Rome, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyIntroduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden.Methods: This multicenter, prospective study evaluated the effectiveness and safety of tildrakizumab 200 mg in patients with moderate-to-severe psoriasis, focusing on those with specific challenges: body weight over 90 kg, baseline PASI ≥20, and difficult-to-treat areas. The study also compared bio-naive versus bio-experienced and male versus female patients. Adults received tildrakizumab 200 mg subcutaneously at weeks 0 and 4, then every 12 weeks.Results: Clinical improvements were assessed using PASI, DLQI, genital PASI, and NAPSI scores. After 24 weeks, the mean PASI score dropped from 14.6 to 0.4, with PASI 90 and PASI 100 scores exceeding 80% (100.0% and 80.3%, respectively). DLQI scores improved from 14.2 to 1.8, and significant improvements were seen in genital PASI and NAPSI scores. No significant adverse events occurred.Conclusions: Tildrakizumab 200 has been shown to be an effective therapeutic option, particularly for patients with high body weight, significant disease burden, and involvement of sensitive areas with no new safety signals.https://www.tandfonline.com/doi/10.1080/09546634.2024.2420825Effectivenesspsoriasistildrakizumabtildrakizumab 200 mganti-IL23 |
| spellingShingle | Annunziata Dattola Nicoletta Bernardini Francesca Svara Anna Balato Giacomo Caldarola Domenico D’Amico Clara De Simone Eugenia Veronica Di Brizzi Maria Esposito Claudia Giofrè Domenico Giordano Claudio Guarneri Francesco Loconsole Viviana Lora Gaia Moretta Diego Orsini Severino Persechino Concetta Potenza Simone Ragonesi Giovanni Pellacani Ketty Peris Maria Concetta Fargnoli Antonio Giovanni Richetta Effectiveness of tildrakizumab 200 mg: an Italian multicenter study Journal of Dermatological Treatment Effectiveness psoriasis tildrakizumab tildrakizumab 200 mg anti-IL23 |
| title | Effectiveness of tildrakizumab 200 mg: an Italian multicenter study |
| title_full | Effectiveness of tildrakizumab 200 mg: an Italian multicenter study |
| title_fullStr | Effectiveness of tildrakizumab 200 mg: an Italian multicenter study |
| title_full_unstemmed | Effectiveness of tildrakizumab 200 mg: an Italian multicenter study |
| title_short | Effectiveness of tildrakizumab 200 mg: an Italian multicenter study |
| title_sort | effectiveness of tildrakizumab 200 mg an italian multicenter study |
| topic | Effectiveness psoriasis tildrakizumab tildrakizumab 200 mg anti-IL23 |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2420825 |
| work_keys_str_mv | AT annunziatadattola effectivenessoftildrakizumab200mganitalianmulticenterstudy AT nicolettabernardini effectivenessoftildrakizumab200mganitalianmulticenterstudy AT francescasvara effectivenessoftildrakizumab200mganitalianmulticenterstudy AT annabalato effectivenessoftildrakizumab200mganitalianmulticenterstudy AT giacomocaldarola effectivenessoftildrakizumab200mganitalianmulticenterstudy AT domenicodamico effectivenessoftildrakizumab200mganitalianmulticenterstudy AT claradesimone effectivenessoftildrakizumab200mganitalianmulticenterstudy AT eugeniaveronicadibrizzi effectivenessoftildrakizumab200mganitalianmulticenterstudy AT mariaesposito effectivenessoftildrakizumab200mganitalianmulticenterstudy AT claudiagiofre effectivenessoftildrakizumab200mganitalianmulticenterstudy AT domenicogiordano effectivenessoftildrakizumab200mganitalianmulticenterstudy AT claudioguarneri effectivenessoftildrakizumab200mganitalianmulticenterstudy AT francescoloconsole effectivenessoftildrakizumab200mganitalianmulticenterstudy AT vivianalora effectivenessoftildrakizumab200mganitalianmulticenterstudy AT gaiamoretta effectivenessoftildrakizumab200mganitalianmulticenterstudy AT diegoorsini effectivenessoftildrakizumab200mganitalianmulticenterstudy AT severinopersechino effectivenessoftildrakizumab200mganitalianmulticenterstudy AT concettapotenza effectivenessoftildrakizumab200mganitalianmulticenterstudy AT simoneragonesi effectivenessoftildrakizumab200mganitalianmulticenterstudy AT giovannipellacani effectivenessoftildrakizumab200mganitalianmulticenterstudy AT kettyperis effectivenessoftildrakizumab200mganitalianmulticenterstudy AT mariaconcettafargnoli effectivenessoftildrakizumab200mganitalianmulticenterstudy AT antoniogiovannirichetta effectivenessoftildrakizumab200mganitalianmulticenterstudy |